Puma Biotechnology, Inc.
NASDAQ:PBYIBiotechnology
+$0.16 today
- Market cap
- $373.26M
- Beta
- 1.21
- P/E (TTM)
- 15.4
- EPS (TTM)
- $0.48
Volume 0.45M
Average 0.26M
PBYI Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Puma Biotechnology, Inc.NASDAQ: PBYI
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 340.2% from a year ago
Other current liabilities stood at $40.16M at the end of Q1 FY2026, up 340.2% from a year earlier and up 143.4% from the prior quarter. Over 3 fiscal years it compounded at +7.4% a year.
Context
- Other current liabilities amounted to 20.8% of total assets at the end of Q1 FY2026, up 16.2 pp from a year earlier.
- Other current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +340.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 16.5M USD
- Year-over-year change
- +8.7%
- 4-year CAGR
- +10.1%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.5M | +8.7% |
| FY2024 | 2024-12-31 | 15.18M | -65.0% |
| FY2023 | 2023-12-31 | 43.42M | +225.5% |
| FY2022 | 2022-12-31 | 13.34M | +18.8% |
| FY2021 | 2021-12-31 | 11.22M | — |
Other Current Liabilities vs competitors
How PBYI compares with its peers on the latest reported figures
- Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +340.2% is the 2nd highest of 9, against a peer median of +46.9%.
- Other current liabilities amounts to 20.8% of total assets for PBYI, versus a peer median of 2.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $40.16M USD | +340.2% | +7.4% | 20.8% | |
| Mar 2026 | $18.45M USD | — | -8.5% | 8.5% | |
| Jun 2026 | $13M USD | +360.5% | +153.8% | 1.7% | |
| Mar 2026 | $7.91M USD | +146.3% | +74.6% | 3.5% | |
| Mar 2026 | $6.43M USD | — | — | 4.8% | |
| Mar 2026 | $4.53M USD | +248.6% | +9.5% | 9.2% | |
| Mar 2026 | $3.8M USD | -5.1% | +29.6% | 0.9% | |
| Mar 2026 | $1.93M USD | +24.3% | — | 0.6% | |
NBPNovaBridge Biosciences | Dec 2025 | $1.31M USD | +69.6% | -86.6% | 3.5% |
| Sep 2026 | $0 USD | -100.0% | +0.6% | 0.0% | |
| Mar 2026 | CA$0 CAD | -100.0% | +246.9% | 0.0% | |
| Peer median (excluding PBYI) | — | +46.9% | +19.6% | 2.6% | |
Competitors are the stored peer set for PBYI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 63.13M | 76.2M | 84.59M | 69.22M | 29.64M |
| Short-term Investments | 18.98M | 4.87M | 11.35M | 31.75M | 67.89M |
| Net Receivables | 32.53M | 42.27M | 48.49M | 32.01M | 53.65M |
| Inventory | 7.11M | 4.53M | 7.08M | 8.72M | 5.52M |
| Other Current Assets | 11.43M | 1.95M | 260K | 3.7M | 4M |
| Total Current Assets | 140.02M | 134.28M | 156.19M | 147.66M | 162.69M |
| Property, Plant & Equipment (Net) | 15.77M | 12.51M | 8.65M | 5.09M | 5.56M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 66.13M | 70.61M | 60.87M | 51.13M | 41.39M |
| Long-term Investments | 0 | 0 | 2.09M | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 7.08M | 3.83M |
| Other Non-current Assets | 4.67M | 4.66M | 2.73M | 2.38M | 2.83M |
| Total Non-current Assets | 86.56M | 87.78M | 74.34M | 65.68M | 53.62M |
| Total Assets | 226.59M | 222.06M | 230.53M | 213.33M | 216.3M |
| Account Payables | 11.17M | 6.44M | 6.89M | 5.51M | 5.06M |
| Short-term Debt | 0 | 0 | 34M | 45.33M | 22.52M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 11.22M | 13.34M | 43.42M | 15.18M | 16.5M |
| Total Current Liabilities | 109.59M | 77.48M | 99.38M | 96.11M | 81.25M |
| Long-term Debt | 97.09M | 98.31M | 65.66M | 21.72M | 4.71M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 6.38M | 12.83M | 5.01M | 1.88M | 0 |
| Total Non-current Liabilities | 119.45M | 122.97M | 77.7M | 25.1M | 4.71M |
| Total Liabilities | 229.03M | 200.45M | 177.09M | 121.21M | 85.96M |
| Common Stock | 4K | 5K | 5K | 5K | 5K |
| Retained Earnings | (1.37B) | (1.37B) | (1.35B) | (1.31B) | (1.28B) |
| Accumulated OCI | (2K) | 0 | (4K) | 6K | 36K |
| Other Stockholders Equity | 0 | (0) | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (2.45M) | 21.61M | 53.44M | 92.13M | 130.34M |
| Total Debt | 116.64M | 114.28M | 111.49M | 74.08M | 28.55M |
| Net Debt | 53.51M | 38.08M | 26.91M | 4.86M | (1.09M) |
Puma Biotechnology, Inc.
NASDAQ:PBYI
Intrinsic Alpha fair value
Locked
Current Price
$7.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.